Pharmacogenetics of anthracyclines. (scientific article published on 8 June 2016)

Roles of genetic polymorphisms in the folate pathway in childhood acute lymphoblastic leukemia evaluated by Bayesian relevance and effect size analysis.

Q34934593

Modifiable risk factors and major cardiac events among adult survivors of childhood cancer

Q34977801

Doxorubicin pathways: pharmacodynamics and adverse effects

Q35048393

Hyaluronan synthase 3 variant and anthracycline-related cardiomyopathy: a report from the children's oncology group.

Q35086334

Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort

Q35699184

A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer

Q36004460

Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group.

Q36058273

Cardiotoxicity of cancer chemotherapy: implications for children

Q36174517

Pharmacogenomics as a risk mitigation strategy for chemotherapeutic cardiotoxicity

Q36637796

Association of anthracycline-related cardiac histological lesions with NADPH oxidase functional polymorphisms

Q36804526

An introduction to the metabolic determinants of anthracycline cardiotoxicity.

Q36891719

Are survivors of acute lymphoblastic leukemia (ALL) at increased risk of cardiovascular disease?

Q37026846

Reduced cardiorespiratory fitness in adult survivors of childhood acute lymphoblastic leukemia.

Q37051195

Anthracycline associated cardiotoxicity in survivors of childhood cancer

Q37112428

Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia

Q37209968

Overexpression of CYP2J2 provides protection against doxorubicin-induced cardiotoxicity

Q37264451

A discovery study of daunorubicin induced cardiotoxicity in a sample of acute myeloid leukemia patients prioritizes P450 oxidoreductase polymorphisms as a potential risk factor.

Q37293202

Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron

Q37421187

New developments in anthracycline-induced cardiotoxicity.

Q37481832

Pharmacogenetics of target genes across doxorubicin disposition pathway: a review

Q37714938

NAD(P)H: quinone oxidoreductase 1 and its potential protective role in cardiovascular diseases and related conditions

Q37912039

Pharmacogenetics of genes across the doxorubicin pathway.

Q37932556

Cancer pharmacogenomics in children: research initiatives and progress to date.

Q38093137

Cardiac complications of oncologic therapy

Q38151049

Anthracycline-related cardiotoxicity in childhood cancer survivors.

Q38166932

The emerging era of pharmacogenomics: current successes, future potential, and challenges

Q38200683

Cardio-oncology issues among pediatric cancer and stem cell transplant survivors

Q38220011

Chemotherapy-induced cardiotoxicity: detection, prevention, and management

Q38234225

Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities

Q38244395

Cardiotoxicity and cardioprotection in childhood cancer.

Q38250298

Anthracyclines/trastuzumab: new aspects of cardiotoxicity and molecular mechanisms.

Q38431346

Evidence for association of SNPs in ABCB1 and CBR3, but not RAC2, NCF4, SLC28A3 or TOP2B, with chronic cardiotoxicity in a cohort of breast cancer patients treated with anthracyclines

Q41430035

Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma: a pilot study

Q42727098

Influence of the polymorphism in candidate genes on late cardiac damage in patients treated due to acute leukemia in childhood

Q43253475

Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21.

Q46008254

Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children.

Q46409053

Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer

Q46611556

NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity

Q46837798

Occult cardiotoxicity in childhood cancer survivors exposed to anthracycline therapy.

Q51196816

Association of NADPH oxidase polymorphisms with anthracycline-induced cardiotoxicity in the RICOVER-60 trial of patients with aggressive CD20(+) B-cell lymphoma.

Q53564509

Clinical and genetic determinants of anthracycline-induced cardiac iron accumulation

Q56217275

Pharmacogenomic Prediction of Anthracycline-Induced Cardiotoxicity in Children

Q57239656

P433

issue

P304

page(s)

1075-1087

P577

publication date

2016-06-08

P1433

published in

Pharmacogenomics

Q15724625

P1476

title

Pharmacogenetics of anthracyclines

P478

volume

Reverse relations

cites work (P2860)

Q55109360	Draft Genome Sequence of Micromonospora sp. Strain WMMA1996, a Marine Sponge-Associated Bacterium.
Q92064539	Identifying Cancer Patients at Risk for Heart Failure Using Machine Learning Methods
Q90442986	Novel oxazolinoanthracyclines as tumor cell growth inhibitors-Contribution of autophagy and apoptosis in solid tumor cells death
Q38688039	Pharmacogenomics in pediatric acute lymphoblastic leukemia: promises and limitations
Q55518023	Possible roles of genetic variations in chemotherapy related cardiotoxicity in pediatric acute lymphoblastic leukemia and osteosarcoma.

P356	DOI	10.2217/PGS-2016-0036
P698	PubMed publication ID	27266419